HealthMore in Health→
Phase 3 CRISPR Success Gives Gene Editing a New Clinical Milestone
Key Takeaways
- Intellia says its gene-editing treatment for hereditary angioedema succeeded in Phase 3.
- The result is framed as the company’s first Phase 3 CRISPR readout, making it a significant field milestone.
- Detailed data are not included in the supplied text, but the late-stage success marks an important validation step for gene editing.
DE
DT Editorial Team··via endpoints.news